Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies.
| Author | |
|---|---|
| Abstract |
:
Imatinib mesylate can induce rapid tumor regression, increase tumor antigen presentation, and inhibit tumor immunosuppressive mechanisms. CTLA-4 blockade and imatinib synergize in mouse models to reduce tumor volume via intratumoral accumulation of CD8+ T cells. We hypothesized that imatinib combined with ipilimumab would be tolerable and may synergize in patients with advanced cancer. |
| Year of Publication |
:
0
|
| Journal |
:
Journal for immunotherapy of cancer
|
| Volume |
:
5
|
| Number of Pages |
:
35
|
| Date Published |
:
2017
|
| URL |
:
https://jitc.biomedcentral.com/articles/10.1186/s40425-017-0238-1
|
| DOI |
:
10.1186/s40425-017-0238-1
|
| Short Title |
:
J Immunother Cancer
|
| Download citation |
